💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Boceprevir

CHEMBL218394 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
519.7 g/mol
LogP
3.1
Phase
4

A direct-acting antiviral that inhibits the NS3/4A protease enzyme of the hepatitis C virus, blocking viral replication. It was used as part of triple therapy for chronic hepatitis C genotype 1 infection. It has been largely replaced by newer, more effective and better-tolerated all-oral direct-acting antiviral regimens.

分子量

519.7000 g/mol

LogP

3.10

TPSA

151.00 Ų

Lipinski 五规则

符合

治疗领域

Hypertension HIV/AIDS Hepatitis C

作用机制

Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C

                

                

                
                

                    
InChI

                    
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C27H45N5O5

                    

                    
                    

                        
HBD / HBA

                        
4 / 5

                    

                    
                    

                        
可旋转键数

                        
10

                    

                    
                    
                    

                        
重原子数

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
A direct-acting antiviral that inhibits the NS3/4A protease enzyme of the hepatitis C virus, blocking viral replication. It was used as part of triple therapy for chronic hepatitis C genotype 1 infection. It has been largely replaced by newer, more effective and better-tolerated all-oral direct-acting antiviral regimens.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Boceprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL218394.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10324367.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.